Two Sigma Investments LP Sells 291,801 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Two Sigma Investments LP cut its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 32.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 616,800 shares of the company's stock after selling 291,801 shares during the period. Two Sigma Investments LP owned 0.87% of Zentalis Pharmaceuticals worth $1,869,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Voya Investment Management LLC raised its position in Zentalis Pharmaceuticals by 14.1% in the fourth quarter. Voya Investment Management LLC now owns 57,017 shares of the company's stock worth $173,000 after acquiring an additional 7,058 shares during the period. Wells Fargo & Company MN raised its position in shares of Zentalis Pharmaceuticals by 26.8% during the 4th quarter. Wells Fargo & Company MN now owns 34,609 shares of the company's stock valued at $105,000 after purchasing an additional 7,305 shares during the period. Corton Capital Inc. bought a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter valued at $32,000. Northern Trust Corp raised its position in shares of Zentalis Pharmaceuticals by 2.2% during the 4th quarter. Northern Trust Corp now owns 484,738 shares of the company's stock valued at $1,469,000 after purchasing an additional 10,513 shares during the period. Finally, Federated Hermes Inc. raised its position in shares of Zentalis Pharmaceuticals by 2.2% during the 4th quarter. Federated Hermes Inc. now owns 493,982 shares of the company's stock valued at $1,497,000 after purchasing an additional 10,644 shares during the period.

Zentalis Pharmaceuticals Trading Up 10.3%

Shares of Zentalis Pharmaceuticals stock traded up $0.14 on Wednesday, reaching $1.50. 2,225,315 shares of the stock were exchanged, compared to its average volume of 1,562,679. Zentalis Pharmaceuticals, Inc. has a 1-year low of $1.01 and a 1-year high of $11.92. The business has a fifty day moving average price of $1.29 and a two-hundred day moving average price of $2.12. The firm has a market capitalization of $107.93 million, a PE ratio of -0.60 and a beta of 1.81.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, hitting the consensus estimate of ($0.67). Research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ZNTL. Wedbush restated a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $8.24.

Insider Activity at Zentalis Pharmaceuticals

In other news, Director Scott Dunseth Myers acquired 21,000 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The shares were purchased at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the transaction, the director now directly owns 281,192 shares in the company, valued at $393,668.80. This trade represents a 8.07% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.90% of the company's stock.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.